On December 18, Donald Trump signed an executive order initiating a significant shift in federal drug policy by reclassifying marijuana (cannabis) under the federal drug scheduling system. The order moves the plant out of the most restrictive category, Schedule I, to Schedule III under the Controlled Substances Act (CSA). This marks the most meaningful federal cannabis policy change in decades.
What Changed…and What Didn’t
For nearly 55 years, marijuana was federally classified as a Schedule I drug, the same category as heroin and LSD, meaning it was considered to have no accepted medical use and a high potential for abuse. That designation has been a sticking point for scientists, medical researchers, and the legal cannabis industry for years.
Under the new executive order:
- Marijuana will be classified as Schedule III, a category used for substances with moderate to low potential for dependence and recognized medical uses. Examples in this category include certain anabolic steroids and ketamine.
- The shift does not legalize recreational marijuana nationwide, and federal prohibition technically remains in place.
- However, this move loosens federal restrictions, paving the way for:
- Expanded scientific research into medical effects and applications
- Potential tax code benefits for legal cannabis businesses
- Broader access to banking, funding, and financial services
- A possible Medicare reimbursement path for certain CBD treatments under future regulations
Why This Matters
The executive order reflects the growing divide between federal law and state policies. More than 40 states, plus Washington, D.C., have enacted medical or recreational cannabis laws, creating a complex legal landscape. The federal reclassification attempts to modernize outdated policy and reduce research barriers while still stopping short of blanket legalization.
For researchers, reclassification removes a major hurdle: marijuana’s Schedule I status has made it difficult to secure approval and funding for many scientific studies. For businesses, it could lift decades-old regulatory barriers that have restricted banking access and financial planning, although some of those changes likely require further congressional action or regulatory adjustments.
Political and Public Reactions
The announcement has drawn mixed reactions:
- Business and research communities welcomed the decision, saying it acknowledges scientific evidence about medical uses and the societal shift in perceptions of cannabis.
- Some conservative lawmakers, especially within the United States House of Representatives Republican Conference, have criticized the move, arguing that rescheduling sends the wrong message about drug use and could increase social harm.
- Advocacy groups pushing for full legalization say the executive order is a step forward but doesn’t go far enough. They are calling for descheduling or complete removal of cannabis from the Controlled Substances Act.
What’s Next?
The executive order itself doesn’t automatically change federal law; it directs federal agencies (like the Department of Justice and the Drug Enforcement Administration) to implement the reclassification process. Because federal drug scheduling is governed by a combination of statute and administrative rulemaking, it could take months, or longer, before the changes fully take effectMeanwhile, legal and political discussions will continue, including debates over whether true descheduling (removing marijuana entirely from the CSA) should happen instead of merely rescheduling it.
